Biologic agents in psoriasis
No Thumbnail Available
Date
2008-12
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Vakıf Gureba Eğitim ve Araştırma Hastanesi Kliniği
Abstract
Psoriasis is a chronic, inflammatory disease affecting 1-3% of population. Advances in the pathogenesis of psoriasis and biotechnology have led to the development of targeted therapy named biologic agents. in this review, general information on biologic drugs are presented and literature on four biologic agents available in our country for moderate to severe plaque psoriasis has been summarized. Mechanisms of action, indications and dosage, results of clinical studies and safety profiles of each biologic agent are discussed.
Description
Keywords
Dermatology, Adalimumab, Biologics, Efalizumab, Etanercept, Infliximab, Psoriasis, Chronic plaque psoriasis, Randomized controlled-trial, Patient-reported outcomes, Long-term, treatment, Phase-III, Double-blind, Efalizumab therapy, Rheumatoid-arthritis, Open-label, Infliximab monotherapy
Citation
Başkan, E. B. (2008). "Biologic agents in psoriasis". Turkderm Deri Hastaliklari ve Frengi Arsivi, 40(Supplement 2), 42-50